Cart
sales@molnova.com
Imirestat
CAS No. 89391-50-4
Imirestat( AL 1576 | Alcon 1576 | HOE 843 )
Catalog No. M26715 CAS No. 89391-50-4
Imirestat is an aldose reductase inhibitor that can be used in diabetes research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 295 | Get Quote |
|
| 10MG | 507 | Get Quote |
|
| 25MG | 801 | Get Quote |
|
| 50MG | 1107 | Get Quote |
|
| 100MG | 1503 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameImirestat
-
NoteResearch use only, not for human use.
-
Brief DescriptionImirestat is an aldose reductase inhibitor that can be used in diabetes research.
-
DescriptionImirestat is an aldose reductase inhibitor that can be used in diabetes research.(In Vivo):Administration of 1 mg/kg Imirestat increased nerve conduction velocity, however, had no effect on resistance to hypoxic conduction block or deficits in insulin-stimulated Uban-sensitive ATPase activity.
-
In Vitro——
-
In VivoImirestat (1 mg/kg) improves nerve conduction velocity but is without effect upon the resistance to hypoxic conduction blockade or the deficit in insulin-stimulated oubain-sensitive ATPase activity.
-
SynonymsAL 1576 | Alcon 1576 | HOE 843
-
PathwayEndocrinology/Hormones
-
TargetReductase
-
RecptorSIRT1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number89391-50-4
-
Formula Weight286.238
-
Molecular FormulaC15H8F2N2O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 83.33 mg/mL (291.13 mM)
-
SMILESFc1ccc2-c3ccc(F)cc3C3(NC(=O)NC3=O)c2c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Napper AD, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem. 2005 Dec 15;48(25):8045-54.
molnova catalog
related products
-
MK 0434
MK 0434 is an orally active steroidal 5 alpha-reductase inhibitor.
-
BYAKANGELICIN(b)
BYAKANGELICINa main furanocoumarin constituent isolated and characterized as an aldose reductase inhibitorand is effective for the treatment of sugar cataracts and diabetic neuropathy and hence might be useful as a lead compound for the development of new type drugs for clinical use.
-
DL-Glyceraldehyde
Glyceraldehyde is produced from the action of the enzyme glyceraldehyde dehydrogenase which converts glycerol to glyceraldehyde using NADP as a cofactor. When present at sufficiently high levels glyceraldehyde can be a cytotoxin and a mutagen. A cytotoxin is a compound that kills cells.
